nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—CYP2D6—Hydroxyurea—head and neck cancer	0.238	0.564	CbGbCtD
Tapentadol—CYP2C9—Fluorouracil—head and neck cancer	0.0995	0.236	CbGbCtD
Tapentadol—CYP2D6—Vinblastine—head and neck cancer	0.0842	0.2	CbGbCtD
Tapentadol—Balance disorder—Fluorouracil—head and neck cancer	0.011	0.03	CcSEcCtD
Tapentadol—Disorientation—Hydroxyurea—head and neck cancer	0.00677	0.0185	CcSEcCtD
Tapentadol—Dysarthria—Fluorouracil—head and neck cancer	0.00635	0.0173	CcSEcCtD
Tapentadol—Breast disorder—Hydroxyurea—head and neck cancer	0.00547	0.0149	CcSEcCtD
Tapentadol—Euphoric mood—Fluorouracil—head and neck cancer	0.00516	0.0141	CcSEcCtD
Tapentadol—Depression—Vinblastine—head and neck cancer	0.0051	0.0139	CcSEcCtD
Tapentadol—Disorientation—Fluorouracil—head and neck cancer	0.00487	0.0133	CcSEcCtD
Tapentadol—Drug interaction—Docetaxel—head and neck cancer	0.00467	0.0128	CcSEcCtD
Tapentadol—Infestation NOS—Hydroxyurea—head and neck cancer	0.00467	0.0127	CcSEcCtD
Tapentadol—Infestation—Hydroxyurea—head and neck cancer	0.00467	0.0127	CcSEcCtD
Tapentadol—Hypoaesthesia—Vinblastine—head and neck cancer	0.00457	0.0125	CcSEcCtD
Tapentadol—Lethargy—Fluorouracil—head and neck cancer	0.00445	0.0121	CcSEcCtD
Tapentadol—Osteoarthritis—Fluorouracil—head and neck cancer	0.00436	0.0119	CcSEcCtD
Tapentadol—Hallucination—Hydroxyurea—head and neck cancer	0.00417	0.0114	CcSEcCtD
Tapentadol—Irritability—Fluorouracil—head and neck cancer	0.00416	0.0114	CcSEcCtD
Tapentadol—Ataxia—Fluorouracil—head and neck cancer	0.0041	0.0112	CcSEcCtD
Tapentadol—Nasopharyngitis—Fluorouracil—head and neck cancer	0.0039	0.0106	CcSEcCtD
Tapentadol—Angiopathy—Hydroxyurea—head and neck cancer	0.0038	0.0104	CcSEcCtD
Tapentadol—Chills—Hydroxyurea—head and neck cancer	0.00376	0.0103	CcSEcCtD
Tapentadol—Vertigo—Vinblastine—head and neck cancer	0.00359	0.00981	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.0035	0.00956	CcSEcCtD
Tapentadol—Convulsion—Vinblastine—head and neck cancer	0.00347	0.00946	CcSEcCtD
Tapentadol—Hot flush—Docetaxel—head and neck cancer	0.00336	0.00918	CcSEcCtD
Tapentadol—Infestation NOS—Fluorouracil—head and neck cancer	0.00336	0.00917	CcSEcCtD
Tapentadol—Infestation—Fluorouracil—head and neck cancer	0.00336	0.00917	CcSEcCtD
Tapentadol—Menopausal symptoms—Docetaxel—head and neck cancer	0.00333	0.0091	CcSEcCtD
Tapentadol—Visual disturbance—Docetaxel—head and neck cancer	0.00332	0.00907	CcSEcCtD
Tapentadol—Urinary tract infection—Fluorouracil—head and neck cancer	0.00327	0.00892	CcSEcCtD
Tapentadol—Lethargy—Docetaxel—head and neck cancer	0.00321	0.00877	CcSEcCtD
Tapentadol—Convulsion—Hydroxyurea—head and neck cancer	0.00316	0.00863	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00308	0.00842	CcSEcCtD
Tapentadol—Hypoaesthesia—Fluorouracil—head and neck cancer	0.003	0.00819	CcSEcCtD
Tapentadol—Oedema—Hydroxyurea—head and neck cancer	0.00298	0.00813	CcSEcCtD
Tapentadol—Ataxia—Docetaxel—head and neck cancer	0.00296	0.00808	CcSEcCtD
Tapentadol—Infection—Hydroxyurea—head and neck cancer	0.00296	0.00807	CcSEcCtD
Tapentadol—Paraesthesia—Vinblastine—head and neck cancer	0.00293	0.008	CcSEcCtD
Tapentadol—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00292	0.00797	CcSEcCtD
Tapentadol—Skin disorder—Hydroxyurea—head and neck cancer	0.00289	0.00789	CcSEcCtD
Tapentadol—Breast disorder—Docetaxel—head and neck cancer	0.00284	0.00776	CcSEcCtD
Tapentadol—Decreased appetite—Vinblastine—head and neck cancer	0.00284	0.00775	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.00283	0.00774	CcSEcCtD
Tapentadol—Nasopharyngitis—Docetaxel—head and neck cancer	0.00281	0.00768	CcSEcCtD
Tapentadol—Constipation—Vinblastine—head and neck cancer	0.00279	0.00762	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00278	0.00758	CcSEcCtD
Tapentadol—Feeling abnormal—Vinblastine—head and neck cancer	0.00269	0.00734	CcSEcCtD
Tapentadol—Dyspnoea—Hydroxyurea—head and neck cancer	0.00265	0.00725	CcSEcCtD
Tapentadol—Somnolence—Hydroxyurea—head and neck cancer	0.00265	0.00723	CcSEcCtD
Tapentadol—Dyspepsia—Hydroxyurea—head and neck cancer	0.00262	0.00715	CcSEcCtD
Tapentadol—Decreased appetite—Hydroxyurea—head and neck cancer	0.00259	0.00707	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00257	0.00702	CcSEcCtD
Tapentadol—Fatigue—Hydroxyurea—head and neck cancer	0.00257	0.00701	CcSEcCtD
Tapentadol—Constipation—Hydroxyurea—head and neck cancer	0.00255	0.00695	CcSEcCtD
Tapentadol—Vision blurred—Fluorouracil—head and neck cancer	0.00247	0.00676	CcSEcCtD
Tapentadol—Weight decreased—Docetaxel—head and neck cancer	0.00246	0.00672	CcSEcCtD
Tapentadol—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00245	0.0067	CcSEcCtD
Tapentadol—Infestation—Docetaxel—head and neck cancer	0.00243	0.00662	CcSEcCtD
Tapentadol—Infestation NOS—Docetaxel—head and neck cancer	0.00243	0.00662	CcSEcCtD
Tapentadol—Hypersensitivity—Vinblastine—head and neck cancer	0.00241	0.00657	CcSEcCtD
Tapentadol—Asthenia—Vinblastine—head and neck cancer	0.00234	0.00639	CcSEcCtD
Tapentadol—Convulsion—Fluorouracil—head and neck cancer	0.00227	0.00621	CcSEcCtD
Tapentadol—Diarrhoea—Vinblastine—head and neck cancer	0.00223	0.0061	CcSEcCtD
Tapentadol—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00219	0.00599	CcSEcCtD
Tapentadol—Hypoaesthesia—Docetaxel—head and neck cancer	0.00217	0.00591	CcSEcCtD
Tapentadol—Confusional state—Fluorouracil—head and neck cancer	0.00216	0.0059	CcSEcCtD
Tapentadol—Dizziness—Vinblastine—head and neck cancer	0.00216	0.00589	CcSEcCtD
Tapentadol—Urinary tract disorder—Docetaxel—head and neck cancer	0.00215	0.00587	CcSEcCtD
Tapentadol—Oedema—Fluorouracil—head and neck cancer	0.00214	0.00585	CcSEcCtD
Tapentadol—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00214	0.00585	CcSEcCtD
Tapentadol—Connective tissue disorder—Docetaxel—head and neck cancer	0.00214	0.00584	CcSEcCtD
Tapentadol—Asthenia—Hydroxyurea—head and neck cancer	0.00214	0.00583	CcSEcCtD
Tapentadol—Urethral disorder—Docetaxel—head and neck cancer	0.00213	0.00583	CcSEcCtD
Tapentadol—Infection—Fluorouracil—head and neck cancer	0.00213	0.00581	CcSEcCtD
Tapentadol—Nervous system disorder—Fluorouracil—head and neck cancer	0.0021	0.00574	CcSEcCtD
Tapentadol—Visual impairment—Docetaxel—head and neck cancer	0.0021	0.00573	CcSEcCtD
Tapentadol—Tachycardia—Fluorouracil—head and neck cancer	0.00209	0.00571	CcSEcCtD
Tapentadol—Vomiting—Vinblastine—head and neck cancer	0.00208	0.00567	CcSEcCtD
Tapentadol—Headache—Vinblastine—head and neck cancer	0.00205	0.00558	CcSEcCtD
Tapentadol—Diarrhoea—Hydroxyurea—head and neck cancer	0.00204	0.00556	CcSEcCtD
Tapentadol—Eye disorder—Docetaxel—head and neck cancer	0.00203	0.00555	CcSEcCtD
Tapentadol—Cardiac disorder—Docetaxel—head and neck cancer	0.00202	0.00552	CcSEcCtD
Tapentadol—Hypotension—Fluorouracil—head and neck cancer	0.002	0.00547	CcSEcCtD
Tapentadol—Angiopathy—Docetaxel—head and neck cancer	0.00198	0.00539	CcSEcCtD
Tapentadol—Dizziness—Hydroxyurea—head and neck cancer	0.00197	0.00537	CcSEcCtD
Tapentadol—Immune system disorder—Docetaxel—head and neck cancer	0.00197	0.00537	CcSEcCtD
Tapentadol—Mediastinal disorder—Docetaxel—head and neck cancer	0.00196	0.00536	CcSEcCtD
Tapentadol—Chills—Docetaxel—head and neck cancer	0.00195	0.00533	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00195	0.00533	CcSEcCtD
Tapentadol—Nausea—Vinblastine—head and neck cancer	0.00194	0.00529	CcSEcCtD
Tapentadol—Insomnia—Fluorouracil—head and neck cancer	0.00194	0.00529	CcSEcCtD
Tapentadol—Paraesthesia—Fluorouracil—head and neck cancer	0.00192	0.00525	CcSEcCtD
Tapentadol—Dyspnoea—Fluorouracil—head and neck cancer	0.00191	0.00522	CcSEcCtD
Tapentadol—Mental disorder—Docetaxel—head and neck cancer	0.00191	0.00521	CcSEcCtD
Tapentadol—Somnolence—Fluorouracil—head and neck cancer	0.00191	0.0052	CcSEcCtD
Tapentadol—Malnutrition—Docetaxel—head and neck cancer	0.0019	0.00517	CcSEcCtD
Tapentadol—Vomiting—Hydroxyurea—head and neck cancer	0.00189	0.00517	CcSEcCtD
Tapentadol—Dyspepsia—Fluorouracil—head and neck cancer	0.00189	0.00515	CcSEcCtD
Tapentadol—Rash—Hydroxyurea—head and neck cancer	0.00188	0.00512	CcSEcCtD
Tapentadol—Dermatitis—Hydroxyurea—head and neck cancer	0.00188	0.00512	CcSEcCtD
Tapentadol—Headache—Hydroxyurea—head and neck cancer	0.00187	0.00509	CcSEcCtD
Tapentadol—Decreased appetite—Fluorouracil—head and neck cancer	0.00186	0.00509	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00185	0.00505	CcSEcCtD
Tapentadol—Nausea—Hydroxyurea—head and neck cancer	0.00177	0.00483	CcSEcCtD
Tapentadol—Feeling abnormal—Fluorouracil—head and neck cancer	0.00177	0.00482	CcSEcCtD
Tapentadol—Urticaria—Fluorouracil—head and neck cancer	0.0017	0.00465	CcSEcCtD
Tapentadol—Syncope—Docetaxel—head and neck cancer	0.0017	0.00464	CcSEcCtD
Tapentadol—Palpitations—Docetaxel—head and neck cancer	0.00167	0.00457	CcSEcCtD
Tapentadol—Loss of consciousness—Docetaxel—head and neck cancer	0.00167	0.00455	CcSEcCtD
Tapentadol—Cough—Docetaxel—head and neck cancer	0.00165	0.00451	CcSEcCtD
Tapentadol—Convulsion—Docetaxel—head and neck cancer	0.00164	0.00448	CcSEcCtD
Tapentadol—Arthralgia—Docetaxel—head and neck cancer	0.00161	0.0044	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.0016	0.00437	CcSEcCtD
Tapentadol—Hypersensitivity—Fluorouracil—head and neck cancer	0.00158	0.00431	CcSEcCtD
Tapentadol—Dry mouth—Docetaxel—head and neck cancer	0.00158	0.00431	CcSEcCtD
Tapentadol—Confusional state—Docetaxel—head and neck cancer	0.00156	0.00426	CcSEcCtD
Tapentadol—Oedema—Docetaxel—head and neck cancer	0.00155	0.00422	CcSEcCtD
Tapentadol—Anaphylactic shock—Docetaxel—head and neck cancer	0.00155	0.00422	CcSEcCtD
Tapentadol—Infection—Docetaxel—head and neck cancer	0.00154	0.00419	CcSEcCtD
Tapentadol—Shock—Docetaxel—head and neck cancer	0.00152	0.00415	CcSEcCtD
Tapentadol—Nervous system disorder—Docetaxel—head and neck cancer	0.00152	0.00414	CcSEcCtD
Tapentadol—Pruritus—Fluorouracil—head and neck cancer	0.00152	0.00414	CcSEcCtD
Tapentadol—Tachycardia—Docetaxel—head and neck cancer	0.00151	0.00412	CcSEcCtD
Tapentadol—Skin disorder—Docetaxel—head and neck cancer	0.0015	0.0041	CcSEcCtD
Tapentadol—Diarrhoea—Fluorouracil—head and neck cancer	0.00147	0.004	CcSEcCtD
Tapentadol—Hypotension—Docetaxel—head and neck cancer	0.00145	0.00395	CcSEcCtD
Tapentadol—Dizziness—Fluorouracil—head and neck cancer	0.00142	0.00387	CcSEcCtD
Tapentadol—HTR3A—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.00141	0.00665	CbGpPWpGaD
Tapentadol—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00141	0.00385	CcSEcCtD
Tapentadol—Insomnia—Docetaxel—head and neck cancer	0.0014	0.00382	CcSEcCtD
Tapentadol—Paraesthesia—Docetaxel—head and neck cancer	0.00139	0.00379	CcSEcCtD
Tapentadol—Dyspnoea—Docetaxel—head and neck cancer	0.00138	0.00376	CcSEcCtD
Tapentadol—OPRM1—Peptide ligand-binding receptors—GRP—head and neck cancer	0.00138	0.00649	CbGpPWpGaD
Tapentadol—Somnolence—Docetaxel—head and neck cancer	0.00137	0.00375	CcSEcCtD
Tapentadol—Vomiting—Fluorouracil—head and neck cancer	0.00136	0.00372	CcSEcCtD
Tapentadol—Dyspepsia—Docetaxel—head and neck cancer	0.00136	0.00372	CcSEcCtD
Tapentadol—Rash—Fluorouracil—head and neck cancer	0.00135	0.00369	CcSEcCtD
Tapentadol—Dermatitis—Fluorouracil—head and neck cancer	0.00135	0.00369	CcSEcCtD
Tapentadol—Decreased appetite—Docetaxel—head and neck cancer	0.00134	0.00367	CcSEcCtD
Tapentadol—Headache—Fluorouracil—head and neck cancer	0.00134	0.00367	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00134	0.00365	CcSEcCtD
Tapentadol—Fatigue—Docetaxel—head and neck cancer	0.00133	0.00364	CcSEcCtD
Tapentadol—UGT1A9—Phase II conjugation—GSTM1—head and neck cancer	0.00133	0.00626	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00133	0.00625	CbGpPWpGaD
Tapentadol—Constipation—Docetaxel—head and neck cancer	0.00132	0.00361	CcSEcCtD
Tapentadol—CYP2D6—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.00132	0.00624	CbGpPWpGaD
Tapentadol—Feeling abnormal—Docetaxel—head and neck cancer	0.00127	0.00348	CcSEcCtD
Tapentadol—Nausea—Fluorouracil—head and neck cancer	0.00127	0.00348	CcSEcCtD
Tapentadol—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—YAP1—head and neck cancer	0.00126	0.00595	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00124	0.00587	CbGpPWpGaD
Tapentadol—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	0.00117	0.0055	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—KISS1—head and neck cancer	0.00115	0.00543	CbGpPWpGaD
Tapentadol—Hypersensitivity—Docetaxel—head and neck cancer	0.00114	0.00311	CcSEcCtD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00112	0.00528	CbGpPWpGaD
Tapentadol—Asthenia—Docetaxel—head and neck cancer	0.00111	0.00303	CcSEcCtD
Tapentadol—Pruritus—Docetaxel—head and neck cancer	0.00109	0.00299	CcSEcCtD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00109	0.00515	CbGpPWpGaD
Tapentadol—UGT2B7—NRF2 pathway—GSTM1—head and neck cancer	0.00109	0.00514	CbGpPWpGaD
Tapentadol—SLC6A4—NRF2 pathway—GSTM1—head and neck cancer	0.00107	0.00506	CbGpPWpGaD
Tapentadol—Diarrhoea—Docetaxel—head and neck cancer	0.00106	0.00289	CcSEcCtD
Tapentadol—UGT1A9—PPARA activates gene expression—CYP1A1—head and neck cancer	0.00105	0.00497	CbGpPWpGaD
Tapentadol—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CYP1A1—head and neck cancer	0.00103	0.00486	CbGpPWpGaD
Tapentadol—Dizziness—Docetaxel—head and neck cancer	0.00102	0.00279	CcSEcCtD
Tapentadol—OPRK1—GPCR ligand binding—KISS1—head and neck cancer	0.00101	0.00476	CbGpPWpGaD
Tapentadol—Vomiting—Docetaxel—head and neck cancer	0.000983	0.00268	CcSEcCtD
Tapentadol—Rash—Docetaxel—head and neck cancer	0.000975	0.00266	CcSEcCtD
Tapentadol—Dermatitis—Docetaxel—head and neck cancer	0.000974	0.00266	CcSEcCtD
Tapentadol—Headache—Docetaxel—head and neck cancer	0.000969	0.00265	CcSEcCtD
Tapentadol—UGT2B7—Biological oxidations—GSTM1—head and neck cancer	0.000956	0.00451	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—GRP—head and neck cancer	0.000948	0.00447	CbGpPWpGaD
Tapentadol—UGT2B7—Metapathway biotransformation—GSTM1—head and neck cancer	0.000943	0.00445	CbGpPWpGaD
Tapentadol—CYP2C19—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000939	0.00443	CbGpPWpGaD
Tapentadol—CYP2C19—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.00093	0.00439	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.000922	0.00435	CbGpPWpGaD
Tapentadol—SLC6A2—NRF2 pathway—GSTM1—head and neck cancer	0.000922	0.00435	CbGpPWpGaD
Tapentadol—Nausea—Docetaxel—head and neck cancer	0.000919	0.00251	CcSEcCtD
Tapentadol—UGT2B7—Biological oxidations—CYP1A1—head and neck cancer	0.000906	0.00427	CbGpPWpGaD
Tapentadol—UGT2B7—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000894	0.00421	CbGpPWpGaD
Tapentadol—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	0.000891	0.0042	CbGpPWpGaD
Tapentadol—UGT1A9—NRF2 pathway—GSTM1—head and neck cancer	0.000885	0.00418	CbGpPWpGaD
Tapentadol—CYP2C9—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000856	0.00404	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—KISS1—head and neck cancer	0.000853	0.00402	CbGpPWpGaD
Tapentadol—CYP2C9—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000848	0.004	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—TYMS—head and neck cancer	0.00084	0.00396	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—GRP—head and neck cancer	0.000831	0.00392	CbGpPWpGaD
Tapentadol—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000804	0.00379	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—UROD—head and neck cancer	0.000797	0.00376	CbGpPWpGaD
Tapentadol—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000793	0.00374	CbGpPWpGaD
Tapentadol—UGT1A9—Biological oxidations—GSTM1—head and neck cancer	0.000777	0.00366	CbGpPWpGaD
Tapentadol—UGT1A9—Metapathway biotransformation—GSTM1—head and neck cancer	0.000766	0.00361	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000757	0.00357	CbGpPWpGaD
Tapentadol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000739	0.00349	CbGpPWpGaD
Tapentadol—CYP2C19—Biological oxidations—NAT2—head and neck cancer	0.000739	0.00349	CbGpPWpGaD
Tapentadol—UGT1A9—Biological oxidations—CYP1A1—head and neck cancer	0.000736	0.00347	CbGpPWpGaD
Tapentadol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000733	0.00346	CbGpPWpGaD
Tapentadol—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000729	0.00344	CbGpPWpGaD
Tapentadol—CYP2C19—Metapathway biotransformation—NAT2—head and neck cancer	0.000729	0.00344	CbGpPWpGaD
Tapentadol—UGT1A9—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000726	0.00342	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	0.000724	0.00341	CbGpPWpGaD
Tapentadol—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000723	0.00341	CbGpPWpGaD
Tapentadol—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CYP1A1—head and neck cancer	0.00071	0.00335	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—GRP—head and neck cancer	0.000702	0.00331	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—NAT2—head and neck cancer	0.00068	0.00321	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—NAT2—head and neck cancer	0.000674	0.00318	CbGpPWpGaD
Tapentadol—CYP2D6—Metapathway biotransformation—NAT2—head and neck cancer	0.00067	0.00316	CbGpPWpGaD
Tapentadol—CYP2C9—Metapathway biotransformation—NAT2—head and neck cancer	0.000665	0.00313	CbGpPWpGaD
Tapentadol—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000651	0.00307	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—KISS1—head and neck cancer	0.00065	0.00307	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—UROD—head and neck cancer	0.000648	0.00305	CbGpPWpGaD
Tapentadol—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000599	0.00283	CbGpPWpGaD
Tapentadol—OPRM1—IL4-mediated signaling events—PIK3CA—head and neck cancer	0.000596	0.00281	CbGpPWpGaD
Tapentadol—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000594	0.0028	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—KISS1—head and neck cancer	0.000591	0.00279	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—KISS1—head and neck cancer	0.00057	0.00269	CbGpPWpGaD
Tapentadol—OPRM1—Opioid Signalling—MAPK1—head and neck cancer	0.000554	0.00262	CbGpPWpGaD
Tapentadol—CYP2C19—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000553	0.00261	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—GRP—head and neck cancer	0.000536	0.00253	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—MAPK3—head and neck cancer	0.000536	0.00253	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—KISS1—head and neck cancer	0.000518	0.00244	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—MAPK1—head and neck cancer	0.00051	0.0024	CbGpPWpGaD
Tapentadol—CYP2C9—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000504	0.00238	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000502	0.00237	CbGpPWpGaD
Tapentadol—OPRM1—IL4-mediated signaling events—AKT1—head and neck cancer	0.000487	0.0023	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—GRP—head and neck cancer	0.000486	0.00229	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—KISS1—head and neck cancer	0.000482	0.00227	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—GRP—head and neck cancer	0.00047	0.00222	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	0.000452	0.00213	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—KISS1—head and neck cancer	0.000438	0.00206	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—GRP—head and neck cancer	0.000427	0.00201	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—HRAS—head and neck cancer	0.000409	0.00193	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—PTEN—head and neck cancer	0.000408	0.00193	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—GRP—head and neck cancer	0.000397	0.00187	CbGpPWpGaD
Tapentadol—CYP2C19—Biological oxidations—GSTM1—head and neck cancer	0.000365	0.00172	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—AKT1—head and neck cancer	0.000361	0.0017	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—GRP—head and neck cancer	0.000361	0.0017	CbGpPWpGaD
Tapentadol—CYP2C19—Metapathway biotransformation—GSTM1—head and neck cancer	0.00036	0.0017	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KISS1—head and neck cancer	0.000349	0.00165	CbGpPWpGaD
Tapentadol—CYP2C19—Biological oxidations—CYP1A1—head and neck cancer	0.000346	0.00163	CbGpPWpGaD
Tapentadol—CYP2C19—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000341	0.00161	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—GSTM1—head and neck cancer	0.000336	0.00158	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	0.000333	0.00157	CbGpPWpGaD
Tapentadol—CYP2D6—Metapathway biotransformation—GSTM1—head and neck cancer	0.000331	0.00156	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—NAT2—head and neck cancer	0.000331	0.00156	CbGpPWpGaD
Tapentadol—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	0.000328	0.00155	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—CYP1A1—head and neck cancer	0.000318	0.0015	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	0.000316	0.00149	CbGpPWpGaD
Tapentadol—CYP2D6—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000314	0.00148	CbGpPWpGaD
Tapentadol—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000311	0.00147	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KISS1—head and neck cancer	0.000306	0.00144	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—UROD—head and neck cancer	0.000304	0.00144	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—DPYD—head and neck cancer	0.00029	0.00137	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—GRP—head and neck cancer	0.000287	0.00136	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000286	0.00135	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000283	0.00133	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—UROD—head and neck cancer	0.00028	0.00132	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—STAT6—head and neck cancer	0.000279	0.00132	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—TP53—head and neck cancer	0.000279	0.00131	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—UROD—head and neck cancer	0.000278	0.00131	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—YAP1—head and neck cancer	0.000275	0.0013	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—NAT2—head and neck cancer	0.000269	0.00127	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KISS1—head and neck cancer	0.000259	0.00122	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—GRP—head and neck cancer	0.000252	0.00119	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—YAP1—head and neck cancer	0.000247	0.00116	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—STAT6—head and neck cancer	0.000245	0.00115	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000236	0.00111	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—DPYD—head and neck cancer	0.000236	0.00111	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—YAP1—head and neck cancer	0.000224	0.00106	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—YAP1—head and neck cancer	0.000216	0.00102	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000215	0.00102	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—GRP—head and neck cancer	0.000213	0.001	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—STAT6—head and neck cancer	0.000207	0.000975	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—YAP1—head and neck cancer	0.000183	0.000863	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.000168	0.000793	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—TYMS—head and neck cancer	0.000165	0.00078	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GSTM1—head and neck cancer	0.000163	0.000771	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GPX1—head and neck cancer	0.000157	0.000738	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CYP1A1—head and neck cancer	0.000155	0.000731	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	0.000147	0.000692	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—IL2—head and neck cancer	0.000143	0.000673	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—TYMS—head and neck cancer	0.000134	0.000634	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000134	0.000633	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000133	0.000627	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GSTM1—head and neck cancer	0.000133	0.000626	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL2—head and neck cancer	0.00013	0.000611	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GPX1—head and neck cancer	0.000127	0.0006	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NAT2—head and neck cancer	0.000126	0.000596	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CYP1A1—head and neck cancer	0.000126	0.000594	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—IL2—head and neck cancer	0.000125	0.00059	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000122	0.000577	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000121	0.000571	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NAT2—head and neck cancer	0.000116	0.000548	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NAT2—head and neck cancer	0.000115	0.000544	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL2—head and neck cancer	0.000114	0.000536	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NOTCH1—head and neck cancer	0.000111	0.000525	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—DPYD—head and neck cancer	0.000111	0.000523	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—IL2—head and neck cancer	0.000106	0.000499	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—YAP1—head and neck cancer	0.000105	0.000496	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—MAPK3—head and neck cancer	0.000104	0.000492	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	0.000103	0.000488	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—DPYD—head and neck cancer	0.000102	0.000481	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—DPYD—head and neck cancer	0.000101	0.000477	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—MAPK1—head and neck cancer	9.92e-05	0.000468	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—EGFR—head and neck cancer	9.91e-05	0.000468	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NOTCH1—head and neck cancer	9.76e-05	0.00046	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—YAP1—head and neck cancer	9.67e-05	0.000456	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL2—head and neck cancer	9.61e-05	0.000453	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—YAP1—head and neck cancer	9.59e-05	0.000452	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—PIK3CA—head and neck cancer	9.47e-05	0.000447	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTGS2—head and neck cancer	9.21e-05	0.000435	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—MAPK3—head and neck cancer	9.14e-05	0.000431	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—MAPK1—head and neck cancer	8.69e-05	0.00041	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—EGFR—head and neck cancer	8.69e-05	0.00041	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PIK3CA—head and neck cancer	8.6e-05	0.000406	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—PIK3CA—head and neck cancer	8.31e-05	0.000392	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NOTCH1—head and neck cancer	8.25e-05	0.000389	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTEN—head and neck cancer	8.04e-05	0.000379	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—HRAS—head and neck cancer	7.96e-05	0.000375	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	7.9e-05	0.000373	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AKT1—head and neck cancer	7.74e-05	0.000365	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—MAPK3—head and neck cancer	7.72e-05	0.000364	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL2—head and neck cancer	7.66e-05	0.000361	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PIK3CA—head and neck cancer	7.54e-05	0.000356	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTGS2—head and neck cancer	7.49e-05	0.000353	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCND1—head and neck cancer	7.46e-05	0.000352	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—MAPK1—head and neck cancer	7.35e-05	0.000347	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—EGFR—head and neck cancer	7.35e-05	0.000347	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	7.21e-05	0.00034	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PTEN—head and neck cancer	7.2e-05	0.00034	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AKT1—head and neck cancer	7.03e-05	0.000332	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PIK3CA—head and neck cancer	7.02e-05	0.000331	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—HRAS—head and neck cancer	6.98e-05	0.000329	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	6.89e-05	0.000325	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AKT1—head and neck cancer	6.79e-05	0.00032	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL2—head and neck cancer	6.71e-05	0.000317	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCND1—head and neck cancer	6.55e-05	0.000309	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTEN—head and neck cancer	6.53e-05	0.000308	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VEGFA—head and neck cancer	6.51e-05	0.000307	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—STAT3—head and neck cancer	6.44e-05	0.000304	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CA—head and neck cancer	6.38e-05	0.000301	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTEN—head and neck cancer	6.32e-05	0.000298	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TYMS—head and neck cancer	6.32e-05	0.000298	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	6.28e-05	0.000296	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTM1—head and neck cancer	6.24e-05	0.000294	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AKT1—head and neck cancer	6.16e-05	0.000291	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK3—head and neck cancer	6.16e-05	0.00029	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GPX1—head and neck cancer	5.98e-05	0.000282	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP1A1—head and neck cancer	5.92e-05	0.000279	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—HRAS—head and neck cancer	5.9e-05	0.000278	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK1—head and neck cancer	5.86e-05	0.000276	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EGFR—head and neck cancer	5.86e-05	0.000276	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TYMS—head and neck cancer	5.81e-05	0.000274	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TYMS—head and neck cancer	5.76e-05	0.000272	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTM1—head and neck cancer	5.74e-05	0.000271	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AKT1—head and neck cancer	5.74e-05	0.000271	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VEGFA—head and neck cancer	5.71e-05	0.000269	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTM1—head and neck cancer	5.69e-05	0.000268	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL2—head and neck cancer	5.67e-05	0.000268	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CA—head and neck cancer	5.67e-05	0.000267	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—STAT3—head and neck cancer	5.65e-05	0.000266	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCND1—head and neck cancer	5.53e-05	0.000261	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GPX1—head and neck cancer	5.5e-05	0.000259	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GPX1—head and neck cancer	5.45e-05	0.000257	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP1A1—head and neck cancer	5.44e-05	0.000257	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK3—head and neck cancer	5.4e-05	0.000255	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP1A1—head and neck cancer	5.4e-05	0.000254	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTEN—head and neck cancer	5.34e-05	0.000252	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AKT1—head and neck cancer	5.21e-05	0.000246	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK1—head and neck cancer	5.14e-05	0.000242	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EGFR—head and neck cancer	5.14e-05	0.000242	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CA—head and neck cancer	5.08e-05	0.00024	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—head and neck cancer	4.92e-05	0.000232	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.86e-05	0.000229	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VEGFA—head and neck cancer	4.82e-05	0.000227	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—STAT3—head and neck cancer	4.78e-05	0.000225	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HRAS—head and neck cancer	4.7e-05	0.000222	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AKT1—head and neck cancer	4.63e-05	0.000218	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CA—head and neck cancer	4.61e-05	0.000217	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK3—head and neck cancer	4.56e-05	0.000215	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CA—head and neck cancer	4.46e-05	0.00021	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.43e-05	0.000209	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK1—head and neck cancer	4.34e-05	0.000205	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGFR—head and neck cancer	4.34e-05	0.000205	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—head and neck cancer	4.31e-05	0.000203	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AKT1—head and neck cancer	4.15e-05	0.000196	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HRAS—head and neck cancer	4.12e-05	0.000194	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CA—head and neck cancer	3.77e-05	0.000178	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AKT1—head and neck cancer	3.76e-05	0.000177	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—head and neck cancer	3.64e-05	0.000172	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AKT1—head and neck cancer	3.64e-05	0.000172	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS2—head and neck cancer	3.52e-05	0.000166	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HRAS—head and neck cancer	3.49e-05	0.000164	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS2—head and neck cancer	3.24e-05	0.000153	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS2—head and neck cancer	3.21e-05	0.000151	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT1—head and neck cancer	3.08e-05	0.000145	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTEN—head and neck cancer	3.07e-05	0.000145	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTEN—head and neck cancer	2.82e-05	0.000133	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTEN—head and neck cancer	2.8e-05	0.000132	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CA—head and neck cancer	2.17e-05	0.000102	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CA—head and neck cancer	1.99e-05	9.39e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CA—head and neck cancer	1.97e-05	9.31e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AKT1—head and neck cancer	1.77e-05	8.34e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AKT1—head and neck cancer	1.63e-05	7.67e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AKT1—head and neck cancer	1.61e-05	7.61e-05	CbGpPWpGaD
